Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Molecular Medicine, Pharmacotherapy +16

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text

Life Sciences, Hematology, Oncology +16

Anthracycline Dose Intensification in Acute Myeloid Leukemia

Hugo F. Fernández, Zhuoxin Sun, Xiaopan Yao et al. · New England Journal of Medicine · 2009 · 907 citations · Full text

Medicine, Oncology, Pharmacotherapy +13